Irofulven: Difference between revisions
m (Protected "Irofulven": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 25: | Line 25: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
| Line 35: | Line 35: | ||
Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 14(2) 161-167, 1996 | Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 14(2) 161-167, 1996 | ||
[[category:Chemotherapeutic agents]] | [[category:Chemotherapeutic agents]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 16:33, 9 August 2012
|
WikiDoc Resources for Irofulven |
|
Articles |
|---|
|
Most recent articles on Irofulven |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Irofulven at Clinical Trials.gov Clinical Trials on Irofulven at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Irofulven
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Irofulven Discussion groups on Irofulven Directions to Hospitals Treating Irofulven Risk calculators and risk factors for Irofulven
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Irofulven |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Irofulven or 6-hydroxymethylacylfulvene (also known as HMAF of MGI-114) is a substance that is used in the treatment of cancer. It belongs to the family of drugs called alkylating agents.
Irofulven is an analogue of illudin S, a sesquiterpene toxin found in mushrooms of the genus Omphalotus. The compound was oringally synthesized by Dr. Trevor McMorris (UCSD) and found to have anticancer properties by Dr. Michael J Kelner (UCSD).[1]
References
Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 14(2) 161-167, 1996 Template:WH Template:WikiDoc Sources
- ↑ MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD (1997). "Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S". Cancer Res. 57 (2): 279–83. PMID 9000568. Free full text